Drug intelligence / Profile preview

IS-101

Development stage: Preclinical
Lead developer: InvisiShield Technologies
Modality: Small Molecules
Administration: Intranasal

Overview

**IS-101** is an intranasal spray developed as a variant-proof preventative against COVID-19. It functions as a SARS-CoV-2 spike (S) protein inhibitor, targeting the virus at the site of entry in the nasal cavity to block infection early. Initially developed by InvisiShield Technologies Ltd., it is currently in preclinical development with demonstrated ability to reduce proinflammatory cytokines induced by respiratory viruses in vivo.[1][13][20]

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on IS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IS-101.

Explore the full profile